{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T04:10:29Z","timestamp":1761883829510,"version":"build-2065373602"},"reference-count":43,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reumatolog\u00eda Cl\u00ednica (English Edition)"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.reumae.2021.01.006","type":"journal-article","created":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T19:22:07Z","timestamp":1652296927000},"page":"286-292","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Drugs Recommended in Adult Rheumatic Diseases, But Considered for Off-Label Use in Argentina"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6843-5962","authenticated-orcid":false,"given":"Fernando","family":"Villalobos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5297-6334","authenticated-orcid":false,"given":"Carla","family":"Matellan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0898-2224","authenticated-orcid":false,"given":"Gabriel","family":"Sequeira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5704-6777","authenticated-orcid":false,"given":"Eduardo","family":"Kerzberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.reumae.2021.01.006_bib0220","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.farma.2010.06.011","article-title":"Revisi\u00f3n sobre el uso de medicamentos en condiciones no incluidas en su ficha t\u00e9cnica","volume":"35","author":"Garc\u00eda-Sabina","year":"2011","journal-title":"Farm Hosp"},{"key":"10.1016\/j.reumae.2021.01.006_bib0225","unstructured":"ANMAT. Indicaciones m\u00e9dicas fuera de prospecto; 2016. http:\/\/www.anmat.gov.ar\/comunicados\/Indicaciones_de_medicamentos_fp.pdf [accessed 10.10.19]."},{"key":"10.1016\/j.reumae.2021.01.006_bib0230","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1056\/NEJMp0802107","article-title":"Regulating off label drug use-rethinking the role of the FDA","volume":"358","author":"Stafford","year":"2008","journal-title":"NEJM"},{"key":"10.1016\/j.reumae.2021.01.006_bib0235","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.mayocp.2012.04.017","article-title":"Ten common questions (and their answers) about off-label drug use","volume":"87","author":"Wittich","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.reumae.2021.01.006_bib0240","unstructured":"Fundaci\u00f3n Espa\u00f1ola de Reumatolog\u00eda. Que es la reumatolog\u00eda? https:\/\/inforeuma.com\/quienes-somos\/que-es-la-reumatologia\/ [accessed 14.10.19]."},{"key":"10.1016\/j.reumae.2021.01.006_bib0245","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/j.1748-720X.2009.00408.x","article-title":"Off-label prescribing: a call for heightened professional and government oversight","volume":"37","author":"Dresser","year":"2009","journal-title":"J Law Med Ethics"},{"journal-title":"Sociedad Argentina de Reumatolog\u00eda","article-title":"Actualizaci\u00f3n de las gu\u00edas de pr\u00e1ctica cl\u00ednica en el tratamiento de la artritis reumatoidea grupo de estudio de artritis Reumatoidea","year":"2013","key":"10.1016\/j.reumae.2021.01.006_bib0250"},{"key":"10.1016\/j.reumae.2021.01.006_bib0255","first-page":"1","article-title":"Gu\u00edas argentinas de pr\u00e1ctica cl\u00ednica para el diagn\u00f3stico y tratamiento de la Osteoartritis","volume":"21","year":"2010","journal-title":"Revista Argentina de Reumatolog\u00eda"},{"journal-title":"Gu\u00edas argentinas de pr\u00e1ctica cl\u00ednica en el diagn\u00f3stico y tratamiento de la fibromialgia","year":"2016","key":"10.1016\/j.reumae.2021.01.006_bib0260"},{"key":"10.1016\/j.reumae.2021.01.006_bib0265","article-title":"Primer Consenso Argentino sobre diagn\u00f3stico y tratamiento de la nefropat\u00eda l\u00fapica","volume":"22","year":"2011","journal-title":"Rev Arg Reumatol"},{"key":"10.1016\/j.reumae.2021.01.006_bib0270","unstructured":"Sociedad Argentina de Reumatolog\u00eda. Consenso Argentino de Esclerodermia; 2010. http:\/\/reumatologia.org.ar\/guias_practicas.php [accessed 1.10.19]."},{"key":"10.1016\/j.reumae.2021.01.006_bib0275","first-page":"46","article-title":"Gu\u00edas Argentinas para el diagn\u00f3stico, la prevenci\u00f3n y el tratamiento de la Osteoporosis 2015","volume":"77","author":"Schurman","year":"2017","journal-title":"MEDICINA (Buenos Aires)"},{"key":"10.1016\/j.reumae.2021.01.006_bib0280","first-page":"1549","volume":"77","author":"Bernardo","year":"2018","journal-title":"Ann Rheum Dis"},{"journal-title":"Sociedad Argentina de Reumatolog\u00eda","article-title":"Sociedad Argentina de Reumatolog\u00eda Consenso Argentino de Diagn\u00f3stico y tratamiento de S\u00edndrome de Sj\u00f6gren Primario","year":"2017","key":"10.1016\/j.reumae.2021.01.006_bib0285"},{"key":"10.1016\/j.reumae.2021.01.006_bib0290","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2021.01.006_bib0295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.reumae.2021.01.006_bib0300","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/acr.21664","article-title":"American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis","volume":"64","author":"Hahn","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.reumae.2021.01.006_bib0305","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","article-title":"European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update","volume":"75","author":"Gossec","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2021.01.006_bib0310","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.reumae.2021.01.006_bib0315","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/art.39298","article-title":"American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"68","author":"Ward","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.reumae.2021.01.006_bib0320","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2021.01.006_bib0325","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/acr.21773","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.reumae.2021.01.006_bib0330","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2021.01.006_bib0335","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1136\/annrheumdis-2018-213826","article-title":"2018 update of the EULAR recommendations for the management of hand osteoarthritis","volume":"78","author":"Kloppenburg","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2021.01.006_bib0340","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1136\/annrheumdis-2016-210289","article-title":"EULAR\/EFORT recommendations for management of patients older than 50years with a fragility fracture and prevention of subsequent fractures","volume":"76","author":"Lems","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2021.01.006_bib0345","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1136\/annrheumdis-2016-209724","article-title":"EULAR revised recommendations for the management of fibromyalgia","volume":"76","author":"Macfarlane","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2021.01.006_bib0350","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2021.01.006_bib0355","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","article-title":"EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis","volume":"75","author":"Yates","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2021.01.006_bib0360","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1136\/annrheumdis-2015-207492","article-title":"2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative","volume":"74","author":"Dejaco","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2021.01.006_bib0365","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/ard.2010.139360","article-title":"EULAR recommendations for calcium pyrophosphate deposition. Part II: Management","volume":"70","author":"Zhang","year":"2011","journal-title":"Ann Rheum Dis"},{"year":"2017","series-title":"Kelley and Firestein's textbook of rheumatology","author":"Firestein","key":"10.1016\/j.reumae.2021.01.006_bib0370"},{"key":"10.1016\/j.reumae.2021.01.006_bib0375","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00296-018-3931-6","article-title":"Analysis of the data on pregnancy and lactation provided by patient information leaflets of anti-rheumatic drugs in Argentina","volume":"38","author":"Sabando","year":"2018","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.reumae.2021.01.006_bib0380","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1001\/archinte.166.9.1021","article-title":"Off-label prescribing among office-based physicians","volume":"166","author":"Radley","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.reumae.2021.01.006_bib0385","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/rheumatology\/keq207","article-title":"Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0","volume":"50","author":"Carmona","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.reumae.2021.01.006_bib0390","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1177\/0961203311426569","article-title":"Current state of evidence on \u2018off-label\u2019 therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland \u2013 a consensus report","volume":"21","author":"Aringer","year":"2012","journal-title":"Lupus"},{"key":"10.1016\/j.reumae.2021.01.006_bib0395","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.3906\/sag-1609-129","article-title":"A nationwide evaluation of off-label drug utilization in Turkey","volume":"47","author":"\u00d6zdamar","year":"2017","journal-title":"Turk J Med Sci"},{"key":"10.1016\/j.reumae.2021.01.006_bib0400","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/archinternmed.2012.340","article-title":"Drug, patient, and physician characteristics associated with off-label prescribing in primary care","volume":"172","author":"Eguale","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.reumae.2021.01.006_bib0405","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.jaad.2018.09.016","article-title":"Lack of a US Food and Drug Administration indication should not limit access to appropriate treatment","volume":"80","author":"Albrecht","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.reumae.2021.01.006_bib0410","doi-asserted-by":"crossref","first-page":"e1000431","DOI":"10.1371\/journal.pmed.1000431","article-title":"Strategies and practices in off-label marketing of pharmaceuticals: a retrospective analysis of whistleblower complaints","volume":"8","author":"Kesselheim","year":"2011","journal-title":"PLoS Med"},{"key":"10.1016\/j.reumae.2021.01.006_bib0415","first-page":"380","article-title":"A snapshot on the on-label and off-label use of the interleukin-1 inhibitors in Italy among rheumatologists and pediatric rheumatologists: a nationwide multi-center retrospective observational study","volume":"24","author":"Vitale","year":"2016","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.reumae.2021.01.006_bib0420","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1517\/14740338.2015.986455","article-title":"Safety of off-label biologicals in systemic lupus erythematosus","volume":"14","author":"Aringer","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.reumae.2021.01.006_bib0425","doi-asserted-by":"crossref","first-page":"e223","DOI":"10.1371\/journal.pmed.0050223","article-title":"Informed consent and shared decision-making: a requirement to disclose to patients off-label prescriptions","volume":"5","author":"Wilkes","year":"2008","journal-title":"PLoS Med"},{"key":"10.1016\/j.reumae.2021.01.006_bib0430","unstructured":"Ministerio de Economia, Obras y Servicios P\u00fablicos y Ministerio de Salud y Accion Social de la Republica Argentina. Decreto N\u00b0 150\/1992. http:\/\/www.anmat.gov.ar\/webanmat\/Legislacion\/Medicamentos\/Decreto150-1992.pdf [accessed 13.11.20]."}],"container-title":["Reumatolog\u00eda Cl\u00ednica (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173574322000776?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173574322000776?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T03:00:12Z","timestamp":1761879612000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173574322000776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S2173574322000776"],"URL":"https:\/\/doi.org\/10.1016\/j.reumae.2021.01.006","relation":{},"ISSN":["2173-5743"],"issn-type":[{"type":"print","value":"2173-5743"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drugs Recommended in Adult Rheumatic Diseases, But Considered for Off-Label Use in Argentina","name":"articletitle","label":"Article Title"},{"value":"Reumatolog\u00eda Cl\u00ednica (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reumae.2021.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Reumatolog\u00eda y Colegio Mexicano de Reumatolog\u00eda. All rights reserved.","name":"copyright","label":"Copyright"}]}}